LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "nivo chemo" as a keyword



Abstract CT081: Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816

Sign Up to like & get
recommendations! Published in 2023 at "Cancer Research"

DOI: 10.1158/1538-7445.am2023-ct081

Abstract: Background: In the global, randomized phase 3 CheckMate 816 study (NCT02998528), neoadjuvant NIVO + chemo demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and pathologic complete response (pCR) vs chemo in pts… read more here.

Keywords: resectable nsclc; nivo chemo; chemo chemo; checkmate 816 ... See more keywords

Real-world treatment patterns, testing patterns, and clinical outcomes of first-line (1L) therapy for metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (mGC/GEJC/EAC).

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2024.42.3_suppl.275

Abstract: 275 Background: GC/GEJC/EAC are among the leading causes of cancer-related morbidity and mortality worldwide. Nivolumab + fluoropyrimidine- + platinum-containing chemotherapy (NIVO+chemo) has demonstrated superior efficacy in patients with advanced non-HER2-positive (HER2-) GC/GEJC/EAC versus chemo alone… read more here.

Keywords: cancer; mgc gejc; nivo chemo; gejc eac ... See more keywords

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2025.43.4_suppl.398

Abstract: 398 Background: At 4-y follow-up, 1L NIVO + chemo continued to demonstrate clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit vs chemo with acceptable safety in patients (pts) with advanced non-HER2+ GC/GEJC/EAC from… read more here.

Keywords: cancer; chemo; nivo chemo; gejc eac ... See more keywords